VACC News and Press, Vaccitech plc From 09/26/23

2023-09-26 07:38:47 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ:VACC), Lifezone Metals (NYSE:LZM), Globus Maritime Ltd. (NASDAQ:GLBS), Siyata Mobile (NASDAQ:SYTA), ESS Tech (NYSE...

2023-09-26 06:12:00 ET 3 Things to Know to Get Started Trading Penny Stocks Navigating the world of penny stocks can be an exciting venture for investors looking to explore opportunities in the financial markets. Penny stocks , typically stocks valued at less than $5 per share, offe...

2023-09-25 15:34:35 ET More on Vaccitech Seeking Alpha’s Quant Rating on Vaccitech Historical earnings data for Vaccitech Financial information for Vaccitech For further details see: Vaccitech surges despite Morgan Stanley downgrade

2023-09-25 13:00:22 ET Gainers: Vaccitech plc ADR ( VACC ) +93% . ESS Tech ( GWH ) +23% . Flora Growth Corp ( FLGC ) +22% . Avalo Therapeutics ( AVTX ) +22% . Neuraxis ( NRXS ) +19% . American Coastal Insurance Corp ( ACIC ...

2023-09-25 13:00:21 ET Gainers: Vaccitech plc ADR ( VACC ) +93% . ESS Tech GWH +23% . Flora Growth Corp ( FLGC ) +22% . Avalo Therapeutics ( AVTX ) +22% . Neuraxis ( NRXS ) +19% . American Coastal Insurance Corp ACIC +18% . ...

OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, ...

2023-09-11 17:32:50 ET More on Arbutus Biopharma Arbutus Biopharma appoints Karen Sims as chief medical officer Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings data for Arbutus Biopharma Financial information for Arbutus Biopharma...

2023-08-10 10:22:08 ET Vaccitech press release ( NASDAQ: VACC ): Q2 GAAP EPS of -$0.62. Revenue of $0.3M. For further details see: Vaccitech GAAP EPS of -$0.62, revenue of $0.3M

OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, c...

Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitor Two patients developed a non-detectable HBsAg level, which continued eight months after last dose A robust T cell response was gener...